Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorStephanie B. Seminara, MD
About this trial
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.
Eligibility criteria
Qualifiers
Female (ages 18-45 years) or Male (ages 18-60 years)
No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration
For women, negative serum hCG pregnancy test
For cases, diagnosis of post-covid-19 syndrome
Disqualifiers
Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol or the interpretation of results
Active use of illicit drugs (not including marijuana)
For women,
Pregnant
Trial design
Treatments tested in this trial
- Kisspeptin 112-121
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Stephanie B. Seminara, MD
Lead sponsor
Massachusetts General Hospital
Sponsor institution
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Source ClinicalTrials.gov